12.04.2012 - A £180m fund designed to bridge the ‘valley of death’ for medical breakthroughs in the UK will kick off at the end of April
London – A £180m government scheme designed to support collaboration between innovative SMEs and academics for developing solutions to healthcare challenges will open for applications at the end of April, according to announcements by the UK’s Technology Strategy Board The Biomedical Catalyst is a key element of the Strategy for Life Sciences launched by Prime Minister David Cameron in December 2011. It will see the Medical Research Council (MRC) and the Technology Strategy Board working together to take the best British medical breakthroughs through to commercial success. Announcing the opening of the fund at a life sciences roundtable event in Japan, Minister for Universities and Science David Willetts said, “The Government is absolutely committed to ensuring the future success of the UK’s life sciences industry and one of the key challenges is tackling the so-called ‘valley of death’. This exists between the moment that a bright new idea is developed in the laboratory and the point when a new drug or technology can be invested in by the market. The £180 million Biomedical Catalyst program will bridge this funding gap.”Under the Biomedical Catalyst scheme, three categories of grant awards will be available – feasibility, early stage and late stage clinical research. Individual grants to businesses will range from a maximum of £150,000 for feasibility awards to £3 million for early and late stage awards. Projects could focus on stratified therapy development, regenerative medicine, diagnostics, eHealth and mHealth solutions, enabling medical technologies and devices. The announcement complements a £200m VC funding initiative termed Project Sigma launched in March by the British Wellcome Trust .
24.07.2015 Biotech companies across Europe continue to raise cash on the public markets, generating €3bn in total financing proceedings in the first half of 2015. Compared to 2014, this is almost twice as much.
23.07.2015 US money keeps flowing into Europe's biotechs. As the race for the peanut allergy market heats up, NASDAQ listed French biotech DBV has announced the successful closing of US$281m (€256m) share offering for its allergy products.
16.07.2015 Sanofi has announced plans to restructure its business in five standalone global business units starting in January 2016. The goal is to promote growth and help the company launch a catalogue of new drugs over the next five years.
15.07.2015 GlaxoSmithKline (GSK) has become the first drugmaker to join the Francis Crick Institute. It is a consortium made up of six scientific and academic institutes to conduct research and drug development in the UK. The new institute is set to become a world-leading centre of biomedical research and innovation.
10.07.2015 Karolinska Development has slashed the reported value of its portfolio by almost half by revising its valuation model for early stage companies and divesting its shares in pain med maker Pharmanest.
08.07.2015 Horizon Pharma plc. has set its sights on US-American speciality pharma company Depomed Inc. After getting nowhere with the rival’s board, Horizon has now launched a US$3bn hostile bid for the pain and CNS specialist.
07.07.2015 Irish pharma play Allergan plc. is boosting its eye care business by acquiring US-American medtech company Oculeve. Included in the deal are Oculeve’s dry eye disease development programmes.
The BioShake series contains high-speed mixer and thermal mixer for small and very small volumes in microplates and reaction tubes and allows for the first time high precise and efficient mixing in the microliter scale for a wide range of applications. more